Individual Research Projects
- ESR1: Synthesis of dehydroepiandrosterone (DHEA) derivatives substituted by five or six membered-17-spiro substituents. National Hellenic Research Foundation
- ESR2: Synthesis of dehydroepiandrosterone (DHEA) derivatives substituted by three membered-17-spiro substituents. National Hellenic Research Foundation
- ESR3: Computer-aided molecular design. HITS gGmbH, Heidelberg Institute for Theoretical Studies
- ESR4: Modelling of mechanistic effects of neurotrophin modulators. HITS gGmbH, Heidelberg Institute for Theoretical Studies
- ESR5: Production of purified targets and x-ray crystal structure determination of target-ligand complexes. University of Siena
- ESR6: In silico screening and Hit to lead development of small molecules neurotrophin receptors ligands. Université de Caen Normandie
- ESR7: Isolation of new natural neurotrophin mimetics from marine microorganisms. National and Kapodistrian University of Athens
- ESR8: Evaluation of small molecule neurotrophin mimetics in models of neurodegeneration and neuroinflammation. Technische Universität Dresden
- ESR9: Development of Human Cell-Based Models for study of Blood Brain Barrier Molecular Permeability. University of Sheffield
- ESR10: Cell-Based Models for Neurotrophic Therapeutic Testing. UV University of Amsterdam
- ESR11: Evaluation of microneurotrophins activity on neurotrophin receptors and their role in signalling, in in vitro and in vivo neurodegenerative conditions, such as Alzheimer’s Disease. Foundation for Research and Technology Hellas
- ESR12: In vitro and in vivo effects of new synthetic and natural compounds on neural stem cells and adult neurogenesis in Alzheimer’s Disease . Foundation for Research and Technology Hellas
- ESR13: Investigation of the potency of small molecule mimetics of neurotrophins to rescue the reduction in synapse number and the aberrant synapse proteome in mouse models of Alzheimer’s Disease. UV University of Amsterdam
- ESR14: Discovery of new neurotrophin mimics using high-through put screening in amyotrophic lateral sclerosis (ALS) patient-derived in vitro models, and taking forward hit compounds into in vivo models. University of Sheffield
